Indigenous vaccine COVAXIN demonstrates 100 per cent efficacy against severe COVID-19 disease in Phase-3 interim analysis; Shows overall efficacy of 78 per cent
Bharat Biotech and ICMR today announced interim results from Phase – 3 trials of COVAXIN. It has reported overall interim clinical efficacy of 78 per cent of Covaxin. It said that the efficacy of the vaccine against severe COVID-19 disease was 100 per cent.
In a statement, the company said, the second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease. It said, due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe COVID-19 disease.